These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 7907608)
1. Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: pathological and prognostic correlations. Fléjou JF; Paraf F; Muzeau F; Fékété F; Hénin D; Jothy S; Potet F J Clin Pathol; 1994 Jan; 47(1):23-6. PubMed ID: 7907608 [TBL] [Abstract][Full Text] [Related]
2. Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus. Nakamura T; Nekarda H; Hoelscher AH; Bollschweiler E; Harbeck N; Becker K; Siewert JR; Harbec N [corrected to Harbeck N] Cancer; 1994 Apr; 73(7):1785-94. PubMed ID: 7907940 [TBL] [Abstract][Full Text] [Related]
3. Expression of p53 protein in Barrett's adenocarcinoma and adenocarcinoma of the gastric cardia and antrum. Jovanović I; Todorović V; Milosavljević T; Micev M; Pesko P; Bjelović M; Mouzas Y; Tzardi M Vojnosanit Pregl; 2005 Dec; 62(12):879-85. PubMed ID: 16375215 [TBL] [Abstract][Full Text] [Related]
5. Cyclooxygenase-2 is expressed frequently and early in Barrett's oesophagus and associated adenocarcinoma. Lagorce C; Paraf F; Vidaud D; Couvelard A; Wendum D; Martin A; Fléjou JF Histopathology; 2003 May; 42(5):457-65. PubMed ID: 12713622 [TBL] [Abstract][Full Text] [Related]
6. Immunohistological study of cell cycle-related factors, oncogene expression, and cell proliferation in adenocarcinoma developed in Barrett's esophagus. Fujii T; Nakagawa S; Hanzawa M; Sueyoshi S; Fujita H; Shirouzu K; Yamana H Oncol Rep; 2003; 10(2):427-31. PubMed ID: 12579284 [TBL] [Abstract][Full Text] [Related]
7. Overexpression of p53 protein in Barrett's syndrome with malignant transformation. Fléjou JF; Potet F; Muzeau F; Le Pelletier F; Fékété F; Hénin D J Clin Pathol; 1993 Apr; 46(4):330-3. PubMed ID: 8496390 [TBL] [Abstract][Full Text] [Related]
8. Detection of genetic changes in Barrett's adenocarcinoma and Barrett's esophagus by DNA in situ hybridization and immunohistochemistry. Krishnadath KK; Tilanus HW; Alers JC; Mulder AH; van Dekken H Cytometry; 1994 Feb; 15(2):176-84. PubMed ID: 8168405 [TBL] [Abstract][Full Text] [Related]
9. Expression of inflammatory secretory phospholipase A2 and cytosolic phospholipase A2 in premalignant and malignant Barrett's oesophagus. Lagorce-Pagès C; Paraf F; Wendum D; Martin A; Fléjou JF Virchows Arch; 2004 May; 444(5):426-35. PubMed ID: 15045585 [TBL] [Abstract][Full Text] [Related]
10. Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus. Krishnadath KK; Tilanus HW; van Blankenstein M; Bosman FT; Mulder AH J Pathol; 1995 Feb; 175(2):175-80. PubMed ID: 7738712 [TBL] [Abstract][Full Text] [Related]
11. Clinicopathological characteristics of human epidermal growth factor receptor 2-positive Barrett's adenocarcinoma. Tanaka T; Fujimura A; Ichimura K; Yanai H; Sato Y; Takata K; Okada H; Kawano S; Tanabe S; Yoshino T World J Gastroenterol; 2012 Nov; 18(43):6263-8. PubMed ID: 23180947 [TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical study of p53, c-erbB-2, and PCNA in barrett's esophagus with dysplasia and adenocarcinoma arising from experimental acid or alkaline reflux model. Kawaura Y; Tatsuzawa Y; Wakabayashi T; Ikeda N; Matsuda M; Nishihara S J Gastroenterol; 2001 Sep; 36(9):595-600. PubMed ID: 11578062 [TBL] [Abstract][Full Text] [Related]
13. Decrease in Le(x) expression in esophageal adenocarcinomas arising in Barrett's epithelium. Engel U; McCombs R; Stranahan P; Pettijohn D; Hage E Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):245-8. PubMed ID: 9107429 [TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis. Yacoub L; Goldman H; Odze RD Mod Pathol; 1997 Feb; 10(2):105-12. PubMed ID: 9127315 [TBL] [Abstract][Full Text] [Related]
15. p53 expression in Barrett's oesophagus, dysplasia, and adenocarcinoma using antibody DO-7. Symmans PJ; Linehan JM; Brito MJ; Filipe MI J Pathol; 1994 Jul; 173(3):221-6. PubMed ID: 7931842 [TBL] [Abstract][Full Text] [Related]
16. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins. Chatelain D; Fléjou JF Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310 [TBL] [Abstract][Full Text] [Related]
17. Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett's mucosa. Going JJ; Keith WN; Neilson L; Stoeber K; Stuart RC; Williams GH Gut; 2002 Mar; 50(3):373-7. PubMed ID: 11839717 [TBL] [Abstract][Full Text] [Related]
18. Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma-sequence of Barrett's esophagus. Halm U; Tannapfel A; Breitung B; Breidert M; Wittekind CW; Mössner J Hepatogastroenterology; 2000; 47(34):962-6. PubMed ID: 11020858 [TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical assessment of Survivin and Bcl3 expression as potential biomarkers for NF-κB activation in the Barrett metaplasia-dysplasia-adenocarcinoma sequence. Puccio I; Khan S; Butt A; Graham D; Sehgal V; Patel D; Novelli M; Lovat LB; Rodriguez-Justo M; Hamoudi RA Int J Exp Pathol; 2018 Feb; 99(1):10-14. PubMed ID: 29473241 [TBL] [Abstract][Full Text] [Related]
20. Detection of Barrett's adenocarcinoma of the gastric cardia with sucrase isomaltase and p53. Iannettoni MD; Lee SS; Bonnell MR; Sell TL; Whyte RI; Orringer MB; Beer DG Ann Thorac Surg; 1996 Nov; 62(5):1460-5; discussion 1465-6. PubMed ID: 8893584 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]